national stem-cell therapy logo

StemBioSys Announces Launch of NeuroMatrix™, a Technological Leap Forward in Laboratory Production of Functionally Mature Human Neural Cell Types

StemBioSys Logo

SAN ANTONIO, Feb. 13, 2023 /PRNewswire/ — StemBioSys, Inc. (StemBioSys) announced today the launch of NeuroMatrix™, an astrocyte-derived extracellular matrix that enables the culture of human induced pluripotent stem cell (hiPSC) derived and primary neural cell types. StemBioSys designed NeuroMatrix™ to expand the use of iPSC-derived neurons in drug discovery and toxicity testing. “NeuroMatrix™ represents a breakthrough in hiPSC-derived neuronal development […]

Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Vast Potential in Cell Therapy, Disease Modelling, Drug Development and Discovery, Personalized Medicine & Toxicology Testing

Research and Markets Logo

DUBLIN, July 13, 2022 /PRNewswire/ — The “Global Induced Pluripotent Stem Cell (iPSC) Industry Report, 2022” report has been added to ResearchAndMarkets.com’s offering. Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new […]

Seelos Therapeutics Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in an In Vitro Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Dementia with Lewy Bodies

Seelos Therapeutics

NEW YORK, June 9, 2022 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced data demonstrating a statistically significant (p<0.01) 19% downregulation of mRNA and a ~40% reduction of alpha synuclein (α-synuclein) in an in vitro study […]